EN | RU
EN | RU

Help Support

Back

Combination of probucol-mecobalamin tablets found to reduce oxidative stress in diabetic peripheral neuropathy patients

Combination of probucol-mecobalamin tablets found to reduce oxidative stress in diabetic peripheral neuropathy patients Combination of probucol-mecobalamin tablets found to reduce oxidative stress in diabetic peripheral neuropathy patients
Combination of probucol-mecobalamin tablets found to reduce oxidative stress in diabetic peripheral neuropathy patients Combination of probucol-mecobalamin tablets found to reduce oxidative stress in diabetic peripheral neuropathy patients

What's new?

The combination of probucol-mecobalamin tablets effectively improves oxidative stress in patients suffering from diabetic peripheral neuropathy. 

In patients with diabetic peripheral neuropathy, the combined use of probucol and mecobalamin tablets is considerably effective in minimizing oxidative stress, says a prospective trial published in "Neuroscience Letters". Researchers explored the impact of the combination of tablets on oxidative stress in 104 subjects having diabetic peripheral neuropathy that were segregated into either combination group (n = 52) or control group (n = 52).

For three months, all the subjects took mecobalamin tablets after meals. Based on this, individuals in the combination group were given probucol for about three months. The Toronto Clinical Scoring System (TCSS) (symptom, sensory, and reflex scores), adverse reactions, clinical efficacy, oxidative stress indicators [catalase (CAT), superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), malondialdehyde (MDA)], and nerve conduction velocity [sensory nerve conduction velocity (SNCV) and motor nerve conduction velocity (MNCV) of the common peroneal and median nerve] were the observation indicators.

No considerable differences in scores (symptom, sensory, reflex, and total) were witnessed between the groups prior to therapy. After treatment, these scores decreased in the combination group vs. the control group. After treatment, the scores in both the groups were decreased when compared with before treatment.

No vital differences in the nerve conduction velocity (SNCV and NMCV) were noted between the groups prior to therapy. However, the indicators of the combination group were greater than the control group after therapy. These indicators of both the groups after treatment were greater than prior to therapy.

No vital differences in SOD, MDA, GSH-Px, CAT were noted between the two groups before therapy. Following therapy, the CAT, SOD, and GSH-Px were considerably greater while MDA was remarkably lower in the combination group when compared to the control group. After therapy, the CAT, SOD, and GSH-Px in both the groups were remarkably greater while the MDA was lower in comparison with before treatment.

In comparison with the control group, the clinical efficacy of the combination group was much better after therapy. No substantial differences were noted in the occurrence of total adverse reactions between the groups, as shown below:


Thus, in diabetic peripheral neuropathy patients, the combined use of probucol and mecobalamin tablets can reduce the TCSS scores, restore neurological symptoms, sensations, and reflexes, raise nerve transmission speed, and minimize oxidative stress.

Source:

Neuroscience Letters

Article:

Analysis of the effect of probucol-mecobalamin tablets combination on oxidative stress in patients with diabetic peripheral neuropathy

Authors:

Hai-Ying Peng et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: